Effect of Taurine on Glycemic Control in Type I and Type II Diabetic Patients

• ClinicalTrials.gov Identifier: NCT01226537
• Recruitment Status: Unknown
• First Posted: October 22, 2010
• Last Update Posted: November 9, 2012
• Sponsor: Hamad Medical Corporation
• Information provided by (Responsible Party): Hamad Medical Corporation

Study Description

Brief Summary:

Diabetes mellitus (DM) and its vascular complications are the one of the most prevalent diseases in the state of Qatar. It is a multifactorial disease associated with the development of retinopathy, nephropathy, neuropathy, cardiomyopathy, and severe vascular dysfunction. The complications of diabetes are caused by either insulin deficiency (type 1 DM) or insulin resistance (type II DM).Unfortunately, effective and sustainable prevention programs of diabetes are limited, and treatment options for type II DM are restricted. Current therapy is based upon control of blood glucose, cholesterol and triglycerides, primarily through insulin replacement in type I diabetes or oral hypoglycemic agents and/or insulin replacement in type II diabetes. New therapies able to prevent vascular complications of diabetes are needed to decrease the occurrence of end organ damage and improve the quality of life of the people. Safe and effective nutritional supplements that could be given along with the regular treatment of the patients that might reduce the need for insulin replacement therapy provide tighter glucose control and protect against oxidative stress and the vascular pathology associated with diabetes mellitus are the need of the hour. Our hypothesis is that supplementation of Taurine in the diets of diabetic patients might reduce the dose or need for insulin replacement therapy and protect them against oxidative stress that is responsible for the complications of diabetes mellitus.

Condition or disease	Intervention/treatment	Phase
it is a Group of Metabolic Diseases in; Which a Person Has High Blood Sugar, Either; Because the Body Does Not Produce Enough Insulin,; or Because Cells do Not Respond to the Insulin That; is Produced.	Drug: Taurine	Phase 1; Phase 2

Study Design

• Study Type: Interventional (Clinical Trial)
• Estimated Enrollment: 20 participants
• Allocation: Randomized
• Intervention Model: Parallel Assignment
• Masking: Triple (Participant, Care Provider, Investigator)
• Primary Purpose: Treatment
• Official Title: Effect of Taurine on Glycemic Control in Type I and Type II Diabetic Patients
• Study Start Date: November 2012
• Estimated Primary Completion Date: November 2013
• Estimated Study Completion Date: December 2014

Arms and Interventions

Arm	Intervention/treatment
Active Comparator: Diabetes Mellitus type 1 taurine; A total of 20 patients with 10 Type I and 10 type II diabetic will be enrolled in the study.After the preliminary examinations, we will categorize 10 Type I and Type II patients into two groups randomly (each group contain 5 patients).500mg Taurine capsules will be given twice per day for 6 months.	Drug: Taurine; 500 mg taurine capsules twice per day for 6 months
Placebo Comparator: Diabetes mellitus type 1 placebo; A total of 20 patients with 10 Type I and 10 type II diabetic will be enrolled in the study.After the preliminary examinations, we will categorize 10 Type I and Type II patients into two groups randomly (each group contain 5 patients).500mg Taurine capsules will be given twice per day for 6 months.	Drug: Taurine; 500 mg taurine capsules twice per day for 6 months
Active Comparator: Diabetes type 2 taurine; A total of 20 patients with 10 Type I and 10 type II diabetic will be enrolled in the study.After the preliminary examinations, we will categorize 10 Type I and Type II patients into two groups randomly (each group contain 5 patients).500mg Taurine capsules will be given twice per day for 6 months.	Drug: Taurine; 500 mg taurine capsules twice per day for 6 months
Placebo Comparator: Diabetes type 2 placebo; A total of 20 patients with 10 Type I and 10 type II diabetic will be enrolled in the study.After the preliminary examinations, we will categorize 10 Type I and Type II patients into two groups randomly (each group contain 5 patients).500mg Taurine capsules will be given twice per day for 6 months.	Drug: Taurine; 500 mg taurine capsules twice per day for 6 months

Outcome Measures

Primary Outcome Measures :

1. Fasting glucose 2) HbA1c 3) Lipid profile 4) Taurine 5) Insulin 6) Urine Micro albumin 7) Eye test [ Time Frame: 9 months ]
   500mg Taurine capsules will be given twice per day for 6 months. After the medication, each month the following outcomes will be measured Fasting glucose 2) HbA1c 3) Lipid profile 4) Taurine 5) Insulin 6) Urine Micro albumin

Eligibility Criteria

• Ages Eligible for Study: 18 Years to 60 Years (Adult)
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: No

Criteria

Inclusion Criteria:

1. Male or Female
2. Above 18-65 Years of old
3. Known diabetic patients with HbA1c>8.0%
4. People who provide signed informed consent -

Exclusion Criteria:

• 1. Pregnancy 2. Diabetic patients with HbA1c <8.0 % 3. Recent or prospective surgical interventions 4. Complications of Type I and Type II DM, e.g., Active cardiovascular disease, nephropathy, retinopathy, neuropathy 5. People who do not provide signed informed consent

Contacts and Locations

Contacts

Contact: Shajitha Thekkeveetil, PhD; 00974-44395096; sveetil@hmc.org.qa

Contact: Yousef Al Ansari, MD; 00974-2112754; yalansari@hmc.org.qa

Sponsors and Collaborators

Hamad Medical Corporation

More Information

• Responsible Party: Hamad Medical Corporation
• ClinicalTrials.gov Identifier: NCT01226537
• Obsolete Identifiers: NCT01225588
• First Posted: October 22, 2010
• Last Update Posted: November 9, 2012
• Last Verified: November 2012

Keywords provided by Hamad Medical Corporation:

Taurine,Diabetes mellitus,oxidative stress,glycemic control

Additional relevant MeSH terms:

Metabolic Diseases; Hyperglycemia; Glucose Metabolism Disorders